AELIS Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.…
Industry Peers
BiotechnologyKey Statistics
About Aelis Farma (EPA: AELIS)
›
Aelis Farma (EPA: AELIS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 0.8000 EUR on 19 November 2026, down 30.4% over 52 weeks. Its 52-week range is 0.6100 EUR to 2.300 EUR: the price is 65.2% below the high and 31.1% above the low.
Its market capitalisation is 10.91M EUR.
Aelis Farma reports return on equity of -144.9%, an operating margin of -204.9% and revenue up 31.6% year over year.
It holds more cash than debt, a net cash position of 2.24M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.